Eriodictyol-7-O-glucoside
CAS No. : 38965-51-4
(Synonyms: Eriodictyol 7-O-β-D-glucoside)
| Size | Price | Stock |
|---|---|---|
| 1mg | $130 | In-stock |
| 5mg | $320 | In-stock |
| 10mg | $520 | In-stock |
| 25mg | $990 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N3847 |
| M.Wt: | 450.39 |
| Formula: | C21H22O11 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Eriodictyol-7-O-glucoside (Eriodictyol 7-O-β-D-glucoside), a flavonoid, is an Nrf2 activator. Eriodictyol-7-O-glucoside exhibits significant scavenging effects on both hydroxyl radicals and superoxide anions, with IC50 values of 0.28 mM and 0.30 mM, respectively. Eriodictyol-7-O-glucoside increases the nuclear localization of Nrf2 and induces the expression of the Nrf2/ARE-dependent genes. Eriodictyol-7-O-glucoside provides protection against oxygen and glucose deprivation (OGD)-induced oxidative insult. Eriodictyol-7-O-glucoside demonstrates neuroprotective efficacy in a rat model of focal cerebral ischemia (MCAO). Eriodictyol-7-O-glucoside can be used for the study of stroke[1][2][3].
IC50 & Target:Nrf2[1]
In Vitro:Eriodictyol-7-O-glucoside (7.5-60 μM, 16 h) induces ARE-dependent luciferase activity in a dose-dependent manner in MDA-MB-231-ARE-Luc cells[1].
Eriodictyol-7-O-glucoside (0-80 μM, 0-24 h) increases Nrf2 protein level in a time-dependent and dose-dependent manner, while Keap1 level remains relatively unaffected in MDA-MB-231 cells and primary cultured astrocytes[1][[2].
Eriodictyol-7-O-glucoside (0-160 μM, 24 h) does not affect Nrf2 mRNA level but induces mRNA of HO-1, NQO1 and GCLC dose-dependently in MDA-MB-231 cells[1].
Eriodictyol-7-O-glucoside (0-80 μM, 24 h) increases Nrf2 protein level and the protein levels of HO-1, NQO1, and cGCS in a dose-dependent manner in HRMC cells[1].
Eriodictyol-7-O-glucoside (80 μM, 0-4 h) increases Nrf2 protein levels in nucleus with time and decreases Nrf2 levels in cytoplasm gradually in HRMC cells[1].
Eriodictyol-7-O-glucoside (0-80 μM, 24 h) shows a dose-dependent increase in intracellular glutathione levels in HRMC cells and primary cultured astrocytes[1][2].
Eriodictyol-7-O-glucoside (80 μM) cotreatment with Cisplatin (HY-17394) significantly improves cell survival in HRMC cells[1].
Eriodictyol-7-O-glucoside (20-80 μM, pretreatment for 2 h) reduces oxygen and glucose deprivation (OGD)-induced cell death, intracellular ROS levels, and cleaved caspase-3 expression in primary cultured astrocytes[2].
In Vivo:Eriodictyol-7-O-glucoside (30 mg/kg, i.p., once daily, 5 days) demonstrates neuroprotective efficacy in a rat model of focal cerebral ischemia (MCAO)[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Eriodictyol-7-O-glucoside
- Cat. No.:
- HY-N3847
- Quantity:
Your information is safe with us.